



Rx-360 Conference 2018 Draft Agenda

Day ONE – September 25th 2018		
8:00-8:45	Breakfast	
8:45-9:00	Opening remarks – Jim Fries (Rx-360 CEO)	
9:00-9:45	Tom Menighan (American Pharmacists Association) - The frontline pharmacist's view of the supply chain	
9:45-10:30	Nancy Singer - Dangerous Documents: Avoiding Land Mines in Your FDA Records and Emails	
Break 10:30-10:45		
10:45-11:30	Rosemary Gibson (Author, ChinaRx)	
11:30-12:15	Bill Troy (ASQ) – Keynote speaker – Quality Culture	
Lunch 12:15-1:15		
	Quality Track	Supply Chain Track
1:15-1:45	BPOG & Rx-360 Pilot	Vivian Berni (DHL) – Connecting shipment data to patients
1:45-2:15	Jim Henderson (Eli Lilly) & Luc Sergile (Eli Lilly) – Designing Systems for Data Integrity	Johannes Schoen (Boehringer Ingelheim) - Drug counterfeiting and anti-counterfeiting efforts
Break 2:15-2:30		
2:30-3:00	Judith Svarczkopf (Roche) – Medical Device	Jim Yaraborough (BSI) – Global Security
3:00-3:30	Nancy Singer - Handling Stressful Situations During an FDA Inspection	Roger Muse (ANAB) - How accreditation can support global supply chain compliance initiatives
3:30-4:00	Closing Remarks	
4:45-6:15	Happy Hour	



Rx-360 Conference 2018 Draft Agenda

Day TWO – September 26th 2018		
8:00-8:45	Breakfast	
8:45-9:00	Opening remarks – Jim Fries (Rx-360 CEO)	
9:00-9:45	Jim Fries (Rx-360 CEO) – “Town Hall Meeting”	
9:45-10:30	Aura Stewart (Consultant) - Frameworks for Disruptive Innovation	
Break 10:30-10:45		
10:45-11:30	Pepe Rodriguez (Business Excellence Consulting (BEC)) - Data Integrity as a top priority when evaluating your suppliers	
11:30-12:15	Alan Minsk (Arnall Golden Gregory LLP) – Keynote speaker - Regenerative medicine: Quality-related Label and regulatory issues to consider	
Lunch 12:15-1:15		
	Quality Track	Supply Chain Track
1:15-1:45	Steve McCarthy (Sparta) – Digital Transformation Journey	Camille Diges (Unisys) – Block Chain
1:45-2:15	Mark Walker (Sartorius) – Transforming Presentation Skills	Hazel Aranha (Sartorius) – Raw Materials Management: A cornerstone for risk mitigation in virus safety assurance of biopharmaceuticals
Break 2:15-2:30		
2:30-3:30	Panel Discussion Close Out	
3:30-4:00	Closing Remarks	